Please ensure Javascript is enabled for purposes of website accessibility

FDA Rejects BioMarin's Hemophilia Gene Therapy

By Jim Crumly - Aug 19, 2020 at 1:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's bad news for hemophilia A sufferers in the U.S., and for the company's shareholders.

Shares of BioMarin Pharmaceutical (BMRN 0.14%) were down by more than 35% as of 1:50 p.m. EDT Wednesday after the Food and Drug Administration unexpectedly rejected the company's application for valoctocogene roxaparvovec (valrox) as a gene therapy for severe hemophilia A. The complete response letter (CRL) means the FDA won't approve the treatment with the application in its current form.

BioMarin was taken by surprise, saying that the FDA is now requesting a longer period of monitoring data from the phase 3 clinical trial for valrox after having previously agreed with the company about what data would be necessary for approval. The biologics license application for valrox was submitted based on interim data from the phase 3 trial and long-term results from an earlier, phase 1/2 study. The FDA says it wants BioMarin to complete the phase 3 study and submit two-year follow-up safety and efficacy data on all trial participants to provide more evidence for the durability of the treatment's effects.

Man with thumb pointing down.

Image source: Getty Images.

The biotech recently released four-year results from the earlier study, showing that six of the seven participants with the highest dose were free of bleeding episodes in year four after averaging more than 16 bleeds per year before treatment. But the FDA concluded that differences between the two studies limited its ability to rely on the phase 1/2 data to support the durability claims.

The therapy is still likely to be approved in the U.S. eventually, but the FDA's decision will mean a significant delay. Meanwhile, BioMarin is awaiting an approval decision from European health regulators, but the company said in its recent earnings report that the verdict may not come until early 2021.

Jim Crumly owns shares of BioMarin Pharmaceutical. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
$93.09 (0.14%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.